Predictors of sustained virological response after antiviral treatment for hepatitis C recurrence following liver transplantation

Liver Transplantation

Volumn 15, Issue 7, 2009, Pages 782-789

  Cescon, Matteo ^a   Grazi, Gian Luca ^a   Cucchetti, Alessandro ^a   Vetrone, Gaetano ^a   Ravaioli, Matteo ^a   Ercolani, Giorgio ^a   Morelli, Maria Cristina ^a   Piscaglia, Fabio ^a   Tamè, Mariarosa ^a   Pinna, Antonio Daniele ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; AZATHIOPRINE; BASILIXIMAB; CYCLOSPORIN A; DACLIZUMAB; ERYTHROPOIETIN; GRANULOCYTE COLONY STIMULATING FACTOR; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; TACROLIMUS;

ADULT; AGE DISTRIBUTION; AGED; ANTIVIRAL THERAPY; ARTICLE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GENOTYPE; GRAFT FAILURE; GRAFT RECIPIENT; HEMOGLOBIN BLOOD LEVEL; HEMOGLOBINOPATHY; HEPATITIS C; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER CELL CARCINOMA; LIVER FIBROSIS; LIVER GRAFT REJECTION; LIVER ISCHEMIA; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; NEUROLOGIC DISEASE; NEUTROPENIA; ORGAN DONOR; PRIORITY JOURNAL; RECURRENT INFECTION; SIDE EFFECT; SURVIVAL RATE; SURVIVAL TIME;

ADULT; AGED; ANTIVIRAL AGENTS; CYCLOSPORINE; FEMALE; HEPATITIS C; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER FAILURE; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; ODDS RATIO; RECURRENCE; REGRESSION ANALYSIS; TACROLIMUS; TREATMENT OUTCOME;

EID: 68349146136     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.21760     Document Type: Article

References (29)

1. United Network for Organ Sharing. 2004 Annual Report of the U.S. Organ Procurement and Transplantation Network and the Scientific Registry of Transplant Recipients: Transplant Data 1994-2003. Available at: http://www.optn.org/data/annualreport.asp. Accessed April 2005.
2. Adam R, McMaster P, O'Grady JG, Castaing D, Klempnauer JL, Jamieson N, et al. Evolution of liver transplantation in Europe: report of the European Liver Transplant Registry. Liver Transpl 2003;9:1231-1243.
3. Gane EJ, Portmann B, Naoumov N, Smith HM, Underhill JA, Donaldson PT, et al. Long-term outcome of hepatitis C infection after liver transplantation. N Engl J Med 1996; 334:815-820.
4. Everhart JE, Wei Y, Eng H, Charlton MR, Persing DH, Wiesner RH, et al. Recurrent and new hepatitis C virus infection after liver transplantation. Hepatology 1999;29: 1220-1226.
5. Kuo A, Terrault NA. Management of hepatitis C in liver transplant recipients. Liver Transpl 2006;6:449-458.
6. Berenguer M, Ferrell L, Watson J, Prieto M. Kim M, Rayon M, et al. HCV-related fibrosis progression following liver transplantation: increase in recent years. J Hepatol 2000; 32:673-684.
7. Neumann UP, Berg T, Bahra M, Seehofer D, Langrehr JM, Neuhaus R, et al. Fibrosis progression after liver transplantation in patients with recurrent hepatitis C. J Hepatol 2004;41:830-836.
8. Wiesner RH, Sorrell M, Villamil F, and the International Liver Transplantation Society Expert Panel. Report of the first International Liver Transplantation Society expert panel consensus conference on liver transplantation and hepatitis C. Liver Transpl 2003;9(suppl 3):S1-S9.
9. Charlton M, Seaberg E. Impact of immunosuppression and acute rejection on recurrence of hepatitis C: results of the National Institute of Diabetes and Kidney Diseases Liver Transplantation Database. Liver Transpl Surg 1999; 5(suppl 1):S107-S114.
10. Burak KW, Kremers WK, Batts KP, Wiesner RH, Rosen CB, Razonable RR, et al. Impact of cytomegalovirus infection, year of transplantation, and donor age on outcomes after liver transplantation for hepatitis C. Liver Transpl 2002; 8:362-369.
11. Charlton M, Seaberg E, Wiesner R, Everhart J, Zetterman R, Lake J, et al. Predictors of patient and graft survival following liver transplantation for hepatitis C. Hepatology 1998;28:823-830.
12. Carrión JA, Navasa M, García-Retortillo M, García-Pagan JC, Crespo G, Bruguera M, et al. Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: a randomized controlled study. Gastroenterology 2007;132:1746-1756.
13. Berenguer M, Royuela A, Zamora J. Immunosuppression with calcineurin inhibitors with respect to the outcome of HCV recurrence after liver transplantation: results of a meta-analysis. Liver Transpl 2007;13:21-29.
14. Watashi K, Hijikata M, Hosaka M, Yamaji M, Shimotohno K. Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes. Hepatology 2003; 38:1282-1288.
15. Sugawara Y, Kaneko J Makuuchi M. Cyclosporin A for treatment of hepatitis C virus after liver transplantation. Transplantation 2006;82:579-580.
16. Firpi RJ, Zhu H, Morelli G, Abdelmalek MF, Soldevila-Pico C, Machicao VI, et al. Ciclosporine suppresses hepatitis C virus in vitro and increases the chance of sustained virological response after liver transplantation. Liver Transpl 2006;12:51-57.
17. Bizollon T, Pradat P, Mabrut JY, Radenne S, Ducerf C, Baulieux J, et al. Histological benefit of retreatment by pegylated interferon alfa-2b and ribavirin in patients with recurrent hepatitis C infection posttransplantation. Am J Transpl 2007;7:448-453.
18. Kamath PS, Wiesner RH, Malinchoc M, Kremers W, Therneau TM, Kosberg CL, et al. A model to predict survival in patients with end-stage liver disease. Hepatology 2001;33: 464-470.
19. Simmonds P, Alberti A, Alter HJ, Bonino F, Bradley DW, Brechot C, et al. A proposed system for the nomenclature of hepatitis C viral genotypes. Hepatology 1994;19:1321-1324.
20. Sreekumar R, Gonzalez-Koch A, Maor-Kendler Y, Batts K, Moreno-Luna L, Poterucha J, et al. Early identification of recipients with progressive histologic recurrence of hepatitis C after liver transplantation. Hepatology 2000;32: 1125-1130.
21. Bedossa P, Poynard T, and the French METAVIR Cooperative Study Group. An algorithm for grading activity in chronic hepatitis C. Hepatology 1996;24:289-293.
22. Tector AJ, Mangus RS, Chestovich P, Vianna R, Fridell JA, Milgrom ML, et al. Use of extended criteria livers decreases wait time for liver transplantation without adversely impacting posttransplant survival. Ann Surg 2006;244:439-450.
23. de Otero J, Gavaldà J, Murio E, Vargas V, Calicó I, Llopart L, et al. Cytomegalovirus disease as a risk factor for graft loss and death after orthotopic liver transplantation. Clin Infect Dis 1998;26:865-870.
24. Vivarelli M, Burra P, La Barba G, Canova D, Senzolo M, Cucchetti A, et al. Influence of steroids on HCV recurrence after liver transplantation: a prospective study. J Hepatol 2007;47:793-798.
25. Neuhaus P, Clavien PA, Kittur D, Salizzoni M, Rimola A, Abeywickrama K, et al. Improved treatment response with basiliximab immunoprophylaxis after liver transplantation: results from a double-blind randomized placebo-controlled trial. Liver Transpl 2002;8:132-142.
26. Klintmalm GB, Washburn WK, Rudic SM, Heffron TG, Teperman LW, Fasola C, et al. Corticosteroid-free immunosuppression with daclizumab in HCV(+) liver transplant recipients: 1-year interim results of the HCV-3 study. Liver Transpl 2007;13:1521-1531.
27. Iacob S, Cicinnati VR, Hilgard P, Iacob RA, Gheorghe LS, Popescu I, et al. Predictors of graft and patient survival in hepatitis C virus (HCV) recipients: model to predict HCV cirrhosis after liver transplantation. Transplantation 2007;84:56-63.
28. Berenguer M, Crippin J, Gish R, Bass N, Bostrom A, Netto G, et al. A model to predict severe HCV-related disease following liver transplantation. Hepatology 2003;38:34-41.
29. Henry SD, Metselaar HJ, Lonsdale RC, Kok A, Haagmans BL, Tilanus HW, et al. Mycophenolic acid inhibits hepatitis C virus replication and acts in synergy with cyclosporin A and interferon-alpha. Gastroenterology 2006;131:1452-1462.